Upgrade to SI Premium - Free Trial

AllianceBernstein (AB)

37.35 +0.33 (0.89%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/22/26)

Latest Headlines

Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Aug 12 August 12, 2026 5:21 PM - SEC Filing AB Announces July 31, 2026 Assets Under Management August 12, 2026 4:05 PM - PR NewsWire Evercore sees July asset manager flows improve on ETF demand August 10, 2026 5:55 AM - StreetInsider Form 4 ALLIANCEBERNSTEIN HOLDIN For: Aug 04 Filed by: Stonehill Charles G.T. August 6, 2026 5:34 PM - SEC Filing Form 144 ALLIANCEBERNSTEIN HOLDIN Filed by: Stonehill Charles G.T. August 4, 2026 3:00 PM - SEC Filing Form 10-Q ALLIANCEBERNSTEIN HOLDIN For: Jun 30 July 31, 2026 4:33 PM - SEC Filing CAIS Welcomes New Strategic Investors, Valuing the Company at Over $2 Billion July 29, 2026 8:30 AM - BizWire Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Jul 28 July 28, 2026 6:24 AM - SEC Filing AllianceBernstein (AB) Reports In-Line Q2 EPS, Misses on Revenue July 28, 2026 6:21 AM - StreetInsider ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES SECOND QUARTER RESULTS July 28, 2026 6:15 AM - PR NewsWire AllianceBernstein (AB) PT Raised to $38 at TD Cowen July 20, 2026 8:09 AM - StreetInsider Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Jul 13 July 13, 2026 4:22 PM - SEC Filing AllianceBernstein AUM rises to $905B at end of June 2026 July 13, 2026 4:05 PM - StreetInsider AB Announces June 30, 2026 Assets Under Management July 13, 2026 4:05 PM - PR NewsWire AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs July 10, 2026 11:49 AM - Globe NewsWire AllianceBernstein (AB) PT Lowered to $37 at TD Cowen July 8, 2026 8:12 AM - StreetInsider AB to Report Second Quarter 2026 Results on July 28, 2026 July 6, 2026 11:28 AM - PR NewsWire AB Science reports phase 1 data for AB8939 plus venetoclax in AML June 29, 2026 1:59 AM - StreetInsider AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML June 29, 2026 1:59 AM - Globe NewsWire AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042 June 17, 2026 12:04 PM - Globe NewsWire Bernstein Private Wealth Management Study Reveals Ultra-Wealthy Families' Focus on Internal Resilience amid Global and Economic Uncertainty June 15, 2026 9:30 AM - PR NewsWire Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Jun 10 June 10, 2026 5:13 PM - SEC Filing AllianceBernstein AUM rises 2% to $899 billion in May 2026 June 10, 2026 4:05 PM - StreetInsider AB Announces May 31, 2026 Assets Under Management June 10, 2026 4:05 PM - PR NewsWire AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS June 9, 2026 12:47 PM - Globe NewsWire Full Article List